Lumbar Spine Mucormycosis Mimicking Pott's Spine: A Case Report
Kanav Gupta1, Kashif Qureshi2, Sonal Gupta3
1Department of Neurosurgery, All India Institute of Medical Sciences (AIIMS), Jammu, India, aiims.edu.
Background:
Spinal mucormycosis is an exceptionally rare form of invasive fungal infection, with fewer than 12 confirmed cases reported in the prior literature. Immunocompromised patients are disproportionately affected, and mortality exceeds 50% in this population. Chronic liver disease as a primary predisposing condition is underrepresented in the existing case series.
Case Presentation:
A 54-year-old male with Child-Pugh Grade C chronic liver cirrhosis, diabetes mellitus, and hypothyroidism presented with progressive low back pain and bilateral lower limb weakness of one week duration. Lumbar MRI demonstrated L2-L3 spondylodiscitis with epidural abscess formation, initially attributed to Pott's spine, and antitubercular therapy (ATT) was initiated empirically. Rapid neurological deterioration prompted surgical re-evaluation. The patient underwent an L3 laminectomy with drainage of an L3-L4 anterior epidural abscess. Intraoperative microscopy revealed aseptate ribbon-like hyphae consistent with Mucorales species. Liposomal Amphotericin B (5 mg/kg/day), intravenous micafungin, and oral posaconazole were commenced. Antifungal therapy was complicated by progressive nephrotoxicity and hepatic decompensation requiring repeated dose modifications. The patient developed hepatic encephalopathy with sepsis and died on Postoperative day (POD) 12 from multiorgan failure.
Conclusion:
This case represents the 12th documented instance of spinal mucormycosis and the first attributable to Child-Pugh Grade C liver disease. In tuberculosis-endemic settings, mucormycosis must be considered in the differential diagnosis of apparent Pott's spine in immunocompromised patients, particularly those with progressive neurological deterioration despite empirical ATT. Concurrent hepatic and renal impairment substantially constrains antifungal options and worsens prognosis. Multidisciplinary coordination and early tissue diagnosis are critical to the management of this rare, life-threatening condition.
Insights
Spinal mucormycosis, a rare fungal infection, is highlighted in a patient with severe liver disease. Early diagnosis and multidisciplinary care are crucial for managing this life-threatening condition in immunocompromised individuals.
Area of Science:
- Infectious Diseases
- Mycology
- Neurosurgery
Background:
- Spinal mucormycosis is an extremely rare invasive fungal infection with high mortality, particularly in immunocompromised patients.
- Chronic liver disease is an underrepresented predisposing factor in reported cases.
- This case represents the 12th documented instance of spinal mucormycosis.
Purpose of the Study:
- To report a unique case of spinal mucormycosis in a patient with Child-Pugh Grade C chronic liver disease.
- To emphasize the diagnostic challenges and management complexities of this rare condition.
Main Methods:
- A 54-year-old male with chronic liver cirrhosis, diabetes, and hypothyroidism presented with back pain and leg weakness.
- Initial diagnosis of Pott's spine led to empirical antitubercular therapy (ATT).
- Surgical intervention and histopathological examination revealed Mucorales species; treatment with liposomal Amphotericin B, micafungin, and posaconazole was initiated.
Main Results:
- The patient experienced rapid neurological deterioration despite ATT.
- Surgical drainage of an epidural abscess confirmed fungal infection.
- Antifungal therapy was complicated by nephrotoxicity and hepatic decompensation, leading to sepsis and multiorgan failure, with death on postoperative day 12.
Conclusions:
- Spinal mucormycosis should be considered in immunocompromised patients with suspected Pott's spine and neurological decline, especially in tuberculosis-endemic areas.
- Concurrent hepatic and renal impairment significantly complicates treatment and worsens prognosis.
- Early tissue diagnosis and multidisciplinary management are vital for improving outcomes in spinal mucormycosis.
